依替巴肽

Eptifibatide was administered intravenously to patients with unstable angina.
Eptifibatide以静脉注射的方式给予不稳定心绞痛患者。
The study evaluated the efficacy of eptifibatide in reducing the risk of recurrent ischemic events.
研究评估了eptifibatide在减少复发性缺血事件方面的功效。
Eptifibatide therapy demonstrated a significant decrease in platelet aggregation.
Eptifibatide治疗显著减少了血小板聚集。
Cardiologists commonly prescribe eptifibatide as an adjunct to standard treatment for acute coronary syndrome.
心脏病专家常在急性冠状综合症的标准治疗中附加使用eptifibatide。
The drug eptifibatide is specifically designed to inhibit the enzyme thromboxane A2 synthase.
药物eptifibatide专门设计用于抑制血栓素A2合成酶。
Eptifibatide administration resulted in a notable improvement in patient outcomes in the clinical trial.
在临床试验中，eptifibatide的使用带来了明显的患者预后改善。
Physicians monitor patients closely during the first few days of eptifibatide treatment due to potential side effects.
由于可能的副作用，医生会在患者开始接受eptifibatide治疗的最初几天密切监测。
Eptifibatide therapy has shown promise in reducing the need for invasive procedures in patients with unstable angina.
Eptifibatide治疗显示出在不稳定心绞痛患者中降低侵入性操作需求的前景。
Researchers compared the effectiveness of eptifibatide with aspirin in preventing cardiovascular events.
研究人员比较了eptifibatide与阿司匹林在预防心血管事件方面的效果。
Despite its benefits, the use of eptifibatide remains limited due to concerns about its cost and potential interactions with other medications.
尽管有其益处，但由于其成本和与其他药物可能产生的相互作用，eptifibatide的使用仍受到限制。